332 related articles for article (PubMed ID: 23415472)
1. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
Lee MR; Wehring HJ; McMahon RP; Linthicum J; Cascella N; Liu F; Bellack A; Buchanan RW; Strauss GP; Contoreggi C; Kelly DL
Schizophr Res; 2013 Apr; 145(1-3):110-5. PubMed ID: 23415472
[TBL] [Abstract][Full Text] [Related]
2. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
3. Oxytocin administration selectively improves olfactory detection thresholds for lyral in patients with schizophrenia.
Woolley JD; Lam O; Chuang B; Ford JM; Mathalon DH; Vinogradov S
Psychoneuroendocrinology; 2015 Mar; 53():217-22. PubMed ID: 25637811
[TBL] [Abstract][Full Text] [Related]
4. A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.
Jarskog LF; Pedersen CA; Johnson JL; Hamer RM; Rau SW; Elliott T; Penn DL
Schizophr Res; 2017 Jul; 185():88-95. PubMed ID: 28094169
[TBL] [Abstract][Full Text] [Related]
5. Negative symptoms of schizophrenia correlate with impairment on the University of Pennsylvania smell identification test.
Ishizuka K; Tajinda K; Colantuoni C; Morita M; Winicki J; Le C; Lin S; Schretlen D; Sawa A; Cascella NG
Neurosci Res; 2010 Jan; 66(1):106-10. PubMed ID: 19819272
[TBL] [Abstract][Full Text] [Related]
6. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia.
Pedersen CA; Gibson CM; Rau SW; Salimi K; Smedley KL; Casey RL; Leserman J; Jarskog LF; Penn DL
Schizophr Res; 2011 Oct; 132(1):50-3. PubMed ID: 21840177
[TBL] [Abstract][Full Text] [Related]
7. Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.
Lee MR; Wehring HJ; McMahon RP; Liu F; Linthicum J; Verbalis JG; Buchanan RW; Strauss GP; Rubin LH; Kelly DL
Schizophr Res; 2016 Apr; 172(1-3):165-8. PubMed ID: 26879587
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.
Feifel D; Macdonald K; Nguyen A; Cobb P; Warlan H; Galangue B; Minassian A; Becker O; Cooper J; Perry W; Lefebvre M; Gonzales J; Hadley A
Biol Psychiatry; 2010 Oct; 68(7):678-80. PubMed ID: 20615494
[TBL] [Abstract][Full Text] [Related]
9. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia.
Gibson CM; Penn DL; Smedley KL; Leserman J; Elliott T; Pedersen CA
Schizophr Res; 2014 Jul; 156(2-3):261-5. PubMed ID: 24799299
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
Zheng W; Zhu XM; Zhang QE; Yang XH; Cai DB; Li L; Li XB; Ng CH; Ungvari GS; Ning YP; Xiang YT
Schizophr Res; 2019 Apr; 206():13-20. PubMed ID: 30573406
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.
Feifel D; Macdonald K; Cobb P; Minassian A
Schizophr Res; 2012 Aug; 139(1-3):207-10. PubMed ID: 22682705
[TBL] [Abstract][Full Text] [Related]
12. Olfactory identification and preference in bipolar disorder and schizophrenia.
Cumming AG; Matthews NL; Park S
Eur Arch Psychiatry Clin Neurosci; 2011 Jun; 261(4):251-9. PubMed ID: 20820794
[TBL] [Abstract][Full Text] [Related]
13. Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia.
Strauss GP; Keller WR; Koenig JI; Gold JM; Ossenfort KL; Buchanan RW
Schizophr Res; 2015 Mar; 162(1-3):57-61. PubMed ID: 25583247
[TBL] [Abstract][Full Text] [Related]
14. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
[TBL] [Abstract][Full Text] [Related]
15. Effects of single dose intranasal oxytocin on social cognition in schizophrenia.
Davis MC; Lee J; Horan WP; Clarke AD; McGee MR; Green MF; Marder SR
Schizophr Res; 2013 Jul; 147(2-3):393-7. PubMed ID: 23676253
[TBL] [Abstract][Full Text] [Related]
16. Effects of intranasal oxytocin on satiety signaling in people with schizophrenia.
Warren KR; Wehring HJ; Liu F; McMahon RP; Chen S; Chester C; Kelly DL
Physiol Behav; 2018 May; 189():86-91. PubMed ID: 29524451
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
Buchanan RW; Kelly DL; Weiner E; Gold JM; Strauss GP; Koola MM; McMahon RP; Carpenter WT
J Clin Psychopharmacol; 2017 Aug; 37(4):394-400. PubMed ID: 28590362
[TBL] [Abstract][Full Text] [Related]
18. Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia.
Buchanan RW; Kelly DL; Strauss GP; Gold JM; Weiner E; Zaranski J; Chen S; Blatt F; Holden J; Granholm E
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):236-243. PubMed ID: 33783399
[TBL] [Abstract][Full Text] [Related]
19. The effect of intranasal oxytocin on neurocognition in people with schizophrenia: A randomized controlled trial.
İmamoğlu A; Stiles BJ; Jarskog LF; Pedersen CA; Elliott T; Penn DL
J Psychiatr Res; 2024 Mar; 171():95-98. PubMed ID: 38262165
[TBL] [Abstract][Full Text] [Related]
20. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
